שולי רווח תפעולי SeaStar Medical Holding Corp (ICU)

SeaStar Medical Holding is developing breakthrough SCD systems to combat hyperinflammation in pediatric intensive care units. The level of operational efficiency demonstrates current profitability, where the latest parameter stands at -692.40. The company is minimizing commercialization risks by adapting devices for lung and kidney therapy. However, ultimate success depends on FDA approval and the willingness of clinics to implement new blood purification methods.
פילוחי מדדים ואנליטיקה של חברת seastarmedical.com (ICU)

Operating margin measures the portion of revenue remaining after covering all production costs before taxes and interest, allowing for an assessment of the business's internal efficiency. The current value of -692.40 reflects the impact of high capacity utilization in the therapeutic device production plants, while the target operating margin demonstrates profit resilience due to equipment modernization that eliminates costly downtime for SeaStar Medical Holding (ICU).